Sugi Predict

Sugi Predict / Compounds / SCHEMBL859599

SCHEMBL859599

SCHEMBL859599

CC(C)(C)OC(=O)N1[C@@H](c2ccccc2)CC[C@H]1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 3/20 0.51
▸ ABCB1 P08183 1/20 0.47
▸ RIPK1 Q13546 2/20 0.45
▸ GPR119 Q8TDV5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183606 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL5156869 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL475744 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL30720983 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL29040317 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL2896922 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL475745 1.00 FFAR2 (0.51) FFAR2ABCB1RIPK1GPR119
SCHEMBL28511990 0.90 ABCB1 (0.49) FFAR2ABCB1RIPK1GPR119
SCHEMBL4870228 0.90 ABCB1 (0.52) ABCB1RIPK1GPR119
SCHEMBL14074143 0.90 ABCB1 (0.52) ABCB1RIPK1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 — — US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 — — US disclosed
CN-114773249-B Compounds, pharmaceutical compositions and methods for treating inflammatory diseases 艾匹克治疗公司 2024-08-16 — — CN disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 — — US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 — — US disclosed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
EP-3533797-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-12-20 — — EP disclosed
US-20060183745-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2006-08-17 — — US disclosed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 — — WO disclosed
US-20050085506-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. 2005-04-21 — — US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6800434-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2004-10-05 — — US disclosed
US-6800434-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2004-10-05 — — US disclosed
US-20040171614-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION 2004-09-02 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
CN-1391473-A VLA-4 inhibitor compounds DAIICHI SEIYAKU CO (JP) 2003-01-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171614-A1 Novel gamma secretase inhibitors BACE1, BACE2, APP FFAR2 2512/4885ABCB1 1091/4885RIPK1 2088/4885
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 FFAR2 733/4885ABCB1 1901/4885RIPK1 3871/4885
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885
US-20060183745-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 FFAR2 77/4885ABCB1 1792/4885RIPK1 2224/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 FFAR2 766/4885ABCB1 2028/4885RIPK1 4049/4885
US-20050085506-A1 Novel gamma secretase inhibitors BACE1, BACE2, APP FFAR2 2694/4885ABCB1 965/4885RIPK1 2190/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.